
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital Schleswig Holstein, Campus Lübeck, in Germany.
The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.
The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival (OS) benefit compared with standard of care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.
Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage 1 to 4 resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.
Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
Published: December 15th 2023 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.